Search

Search Constraints

You searched for: Author/Creator Mookerjee, Bijoyesh

Search Results

11. Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K–mutant advanced or metastatic melanoma. (March 2019)

12. LGG-46. TRAMETINIB THERAPY IN PEDIATRIC PATIENTS WITH LOW-GRADE GLIOMAS (LGG) WITH BRAF GENE FUSION; A DISEASE-SPECIFIC COHORT IN THE FIRST PEDIATRIC TESTING OF TRAMETINIB. Issue 2 (22nd June 2018)

13. LGG-46. TRAMETINIB THERAPY IN PEDIATRIC PATIENTS WITH LOW-GRADE GLIOMAS (LGG) WITH BRAF GENE FUSION; A DISEASE-SPECIFIC COHORT IN THE FIRST PEDIATRIC TESTING OF TRAMETINIB. Issue 2 (22nd June 2018)

14. Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials. (January 2020)

15. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. Issue 5 (May 2019)

17. RARE-11. EFFICACY AND SAFETY OF DABRAFENIB + TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E–MUTATED LOW-GRADE GLIOMA (LGG). (5th November 2018)

18. Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. (September 2017)